Guillain-Barré syndrome.

Area of Science:

• Neurology
• Immunology
• Infectious Diseases

Background:

• Guillain-Barré syndrome is a leading cause of acute flaccid paralysis globally.
• It often follows infections, including upper respiratory tract infections, and has been linked to Campylobacter jejuni, Zika virus, and SARS-CoV-2.
• The pathogenesis involves an autoantibody-mediated immune response, potentially triggered by molecular mimicry.

Purpose of the Study:

• To review the current understanding of Guillain-Barré syndrome.
• To highlight diagnostic challenges and limitations of existing criteria for syndrome variants.
• To discuss treatment outcomes, geographical disparities in care, and future therapeutic directions.

Main Methods:

• Review of existing literature on Guillain-Barré syndrome.
• Analysis of data from the International Guillain-Barré Syndrome Outcome Study.
• Discussion of ongoing clinical trials for novel therapies.

Main Results:

• Classical Guillain-Barré syndrome diagnosis is generally straightforward, but variants may be missed.
• While immunotherapy is effective for most, significant disability and mortality persist.
• Geographical variations in treatment access, particularly in low-income countries, were identified.

Conclusions:

• Improved global access to immunotherapy for Guillain-Barré syndrome is crucial.
• Development of disease-modifying therapies to limit nerve injury is needed.
• Ongoing research and clinical trials, including complement inhibitors, promise to advance understanding and treatment.